Although preliminary regulatory-led analyses of post-marketing data have not found conclusive evidence of a causal link [14], and in the absence of evidence from large, randomised clinical trials, observational studies adequately designed to assess the comparative safety of treatments, employing an active comparator, new user design, are warranted to evaluate the risk of SIS in individuals treated with GLP-1RA
Shimmura C, Suzuki K, Iwata Y, Tsuchiya KJ, Ohno K, Matsuzaki H, Iwata K, Kameno Y, Takahashi T, Wakuda T, Nakamura K, Hashimoto K, Mori N (2013) Enzymes in the glutamate-glutamine cycle in the anterior cingulate cortex in postmortem brain of subjects with autism
Dendritic spine actin cytoskeleton in autism spectrum disorder
Alcohol-related deaths during the COVID-19 pandemic
Customs inspection delays can expose temperature-sensitive compounds to degradation